What is Uremic Gastropathy?
Uremic gastropathy is a gastrointestinal mucosal disorder that develops in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), characterized by gastric mucosal lesions, decreased gastric secretory activity, and pathologic changes including edema, mineralization, and vascular injury to the stomach wall. 1
Pathophysiology and Mechanisms
Uremic gastropathy develops through multiple interconnected mechanisms related to kidney failure:
- Uremic toxin accumulation directly damages gastric mucosa and impairs normal gastric function 1, 2
- Chronic anemia reduces oxygen delivery to gastric tissues
- Fluctuations in gastric blood supply during hemodialysis contribute to mucosal injury 1
- Vascular injury including submucosal arteriopathy with myocyte necrosis, calcification, and thrombosis leads to tissue anoxia 3
- Altered parietal cell function results in decreased gastric acid secretion 2
The condition represents a disease of the mucosal lamina propria, with lesions primarily caused by diffuse vascular injury and altered gastric cell function 3.
Clinical Manifestations
Symptoms
Patients with uremic gastropathy experience uremic symptoms that should be systematically assessed 4:
- Reduced appetite
- Nausea and vomiting
- Fatigue and lethargy
- Abdominal discomfort
Important caveat: Unlike humans where gastric ulceration predominates, frank ulceration is actually uncommon in uremic gastropathy—occurring in only about 4% of cases 5. Most patients have mucosal changes without ulceration 6.
Histopathologic Features
The characteristic pathologic changes include 3, 5:
Mucosal changes:
- Expansion of lamina propria by edema, fibroplasia, and mineralization
- Atrophy of gastric glands with fewer cells per unit of tissue
- Parietal cell swelling with mitochondrial damage and calcification
- Chief cell atrophy with loss of granules
Vascular changes:
- Submucosal arteriopathy with segmental degenerative lesions
- Myocyte necrosis and calcification in muscular arteries
- Thrombosis and obstructive arteriopathy
- Swollen capillary endothelium with extracellular calcium deposits
Distribution: Lesions are typically limited to the gastric body and fundic zones 3
Diagnostic Considerations
Clinical Assessment
According to KDIGO 2024 guidelines, clinicians should 4:
- Ask about uremic symptoms at each consultation using a standardized validated assessment tool
- Screen patients with CKD G4-G5 twice annually for malnutrition using validated tools
- Monitor for involuntary weight loss, frailty, and poor appetite
Imaging Features
Recent veterinary studies (which may inform human understanding) show ultrasonographic features include 7:
- Gastric wall thickening (present in all cases)
- Mucosal hyperechoic bands or stripes suggesting mineralization (most common finding at 48.4%)
- Submucosal thickening with decreased echogenicity suggesting edema
- Association between mucosal mineralization and elevated calcium-phosphorus product
Biochemical Correlations
The severity of gastropathy correlates with 5:
- Blood urea nitrogen (BUN) levels
- Creatinine levels
- Calcium-phosphorus product (Ca × Phos)
- Degree of anemia (hematocrit)
Differential Diagnosis
Critical distinction: Uremic gastropathy must be differentiated from post-transplant gastropathy, as the etiologies and management differ significantly 1:
- Uremic gastropathy (pre-transplant): Caused by uremia, anemia, and dialysis-related vascular changes
- Post-transplant gastropathy: Associated with immunosuppressive therapies (especially mycophenolate mofetil), not uremia
Helicobacter pylori infection is more prevalent in uremic patients than post-transplant patients and may contribute to mucosal injury 1.
Management Approach
Primary Treatment
The cornerstone of management is addressing the underlying kidney failure 4:
- Optimize dialysis adequacy to reduce uremic toxin burden 8
- Correct metabolic derangements (acidosis, hyperparathyroidism) 9
- Manage anemia appropriately
- Consider kidney transplantation for definitive treatment
Symptomatic Management
Based on available evidence 1, 6:
- Acid-controlling therapies (proton pump inhibitors or H2-receptor antagonists) serve as effective prophylaxis
- H. pylori eradication when present may help prevent further mucosal injury
- Nutritional support under supervision of renal dietitians for patients with malnutrition 4
Monitoring
Enable access to multidisciplinary care including 4:
- Dietary counseling
- Medication management
- Regular assessment of nutritional status
- Screening for complications
Prognostic Implications
Important clinical point: Early recognition and intervention for uremic gastropathy helps prevent post-transplant gastrointestinal complications 1. These lesions carry poor prognostic implications as they disrupt GI tract function, which affects pharmacokinetics of immunosuppressive drugs post-transplant, potentially leading to poor graft survival and increased mortality 1.
The prevalence of gastric histopathologic changes in patients with renal failure is high—occurring in approximately 79% of cases—and increases with severity of biochemical derangements 5. However, contrary to older beliefs, patients on maintenance dialysis are not at significantly increased risk of peptic ulceration compared to the general population 6.